Please ensure Javascript is enabled for purposes of website accessibility

Want to Know What Your Heart Defibrillator Is Doing? Abbott Has an App for That

By Brian Orelli, PhD – Feb 18, 2020 at 3:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Remote monitoring should help doctors and patients identify issues earlier.

Abbott (ABT 3.58%) has received European approval for its new Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices for patients with abnormal heart rhythms and heart failure. In addition to all the normal functions of a defibrillator, which shocks a patient's heart back into normal rhythms if it starts beating erratically, the new devices can connect to Abbott's myMerlinPulse mobile app via Bluetooth to give doctors and patients more information on what's happening with the device.

Data from the device is sent straight to the patient's doctor, but the patient can see the transmission history and device performance as well. Patients can also trigger transmissions to their doctors if they feel something is awry. The app can even prompt patients to schedule their next appointments. On the physician side, the automatic transmissions can help doctors identify asymptomatic episodes, which can lead to earlier intervention and potentially better patient outcomes.

"The positive impact of remote monitoring has been proven repeatedly and leads to better patient outcomes and reduced burden on the healthcare system," Avi Fischer, chief medical officer for Abbott's cardiac rhythm management business said in a statement.

Doctor listening to a patient's heart with a stethoscope

Image source: Getty Images.

With connectivity comes risk from hackers and malware, but Abbott has built-in cybersecurity controls. The devices also have the capacity to be upgraded to meet evolving digital threats.

In addition their remote-monitoring capabilities, the Gallant devices have all the bells and whistles of its earlier model defibrillators, including the ability to program the ICD to a patient's specific needs and Abbott's MultiPoint Pacing and SyncAV features in the CRT-D, which increase the likelihood that patients will respond to CRT therapy.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$103.08 (3.58%) $3.56

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.